Kyverna Therapeutics (KYTX) Financials

Kyverna Therapeutics logo
$4.66 -0.10 (-2.10%)
As of 03:35 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Annual Income Statements for Kyverna Therapeutics

Annual Income Statements for Kyverna Therapeutics

This table shows Kyverna Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
-60 -127 -161
Consolidated Net Income / (Loss)
-60 -127 -161
Net Income / (Loss) Continuing Operations
-60 -127 -161
Total Pre-Tax Income
-60 -127 -161
Total Operating Income
-62 -143 -170
Total Gross Profit
0.00 0.00 0.00
Total Revenue
0.00 0.00 0.00
Total Cost of Revenue
0.00 0.00 0.00
Total Operating Expenses
62 143 170
Selling, General & Admin Expense
12 30 36
Research & Development Expense
50 112 134
Total Other Income / (Expense), net
2.04 15 8.52
Interest Expense
0.19 0.14 0.49
Interest & Investment Income
2.28 15 9.09
Other Income / (Expense), net
-0.06 -0.09 -0.09
Basic Earnings per Share
($89.61) ($3.33) ($3.64)
Weighted Average Basic Shares Outstanding
673.62K 38.33M 44.26M
Diluted Earnings per Share
($89.61) ($3.33) ($3.64)
Weighted Average Diluted Shares Outstanding
673.62K 38.33M 44.26M
Weighted Average Basic & Diluted Shares Outstanding
- 43.21M 60.44M

Quarterly Income Statements for Kyverna Therapeutics

This table shows Kyverna Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Total Costs & Expenses
- - - - - - 39 - - - 43
Net Income / (Loss) Attributable to Common Shareholders
-27 -29 -34 -37 -45 -42 -37 -38 -40 -38 -42
Consolidated Net Income / (Loss)
-27 -29 -34 -37 -45 -42 -37 -38 -40 -38 -42
Net Income / (Loss) Continuing Operations
-27 -29 -34 -37 -45 -42 -37 -38 -40 -38 -42
Total Pre-Tax Income
-27 -29 -34 -37 -45 -42 -37 -38 -40 -38 -42
Total Operating Income
-29 -33 -39 -41 -47 -44 -39 -39 -41 -40 -43
Total Gross Profit
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Revenue
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Cost of Revenue
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Operating Expenses
29 33 39 41 47 44 39 39 41 40 43
Selling, General & Admin Expense
6.88 6.11 9.58 7.56 9.98 8.59 8.27 9.27 11 15 16
Research & Development Expense
22 27 29 33 37 36 30 30 30 25 27
Total Other Income / (Expense), net
2.67 4.63 4.28 3.55 2.77 2.33 1.94 1.48 1.64 1.24 0.96
Interest Expense
0.04 0.04 0.03 0.03 0.03 0.01 0.01 0.44 0.67 0.67 0.73
Interest & Investment Income
2.74 4.69 4.36 3.58 2.83 2.36 2.00 1.91 2.33 1.93 1.68
Other Income / (Expense), net
-0.03 -0.02 -0.05 0.00 -0.03 -0.02 -0.05 0.02 -0.02 -0.02 0.01
Basic Earnings per Share
($1.12) ($0.67) ($0.80) ($0.74) ($1.03) ($0.97) ($0.85) ($0.79) ($0.66) ($0.63) ($0.68)
Weighted Average Basic Shares Outstanding
23.75M 43.13M 43.16M 38.33M 43.22M 43.23M 43.42M 44.26M 60.43M 60.90M 61.96M
Diluted Earnings per Share
($1.12) ($0.67) ($0.80) ($0.74) ($1.03) ($0.97) ($0.85) ($0.79) ($0.66) ($0.63) ($0.68)
Weighted Average Diluted Shares Outstanding
23.75M 43.13M 43.16M 38.33M 43.22M 43.23M 43.42M 44.26M 60.43M 60.90M 61.96M
Weighted Average Basic & Diluted Shares Outstanding
43.12M 43.15M 43.17M 43.21M 43.22M 43.25M 43.80M 60.44M 60.80M 61.84M 63.22M

Annual Cash Flow Statements for Kyverna Therapeutics

This table details how cash moves in and out of Kyverna Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
-3.08 62 27
Net Cash From Operating Activities
-52 -114 -154
Net Cash From Continuing Operating Activities
-52 -114 -154
Net Income / (Loss) Continuing Operations
-60 -127 -161
Consolidated Net Income / (Loss)
-60 -127 -161
Depreciation Expense
1.71 2.13 1.80
Amortization Expense
-1.12 -7.66 -6.89
Non-Cash Adjustments To Reconcile Net Income
3.94 11 11
Changes in Operating Assets and Liabilities, net
3.42 7.86 1.42
Net Cash From Investing Activities
-8.79 -161 40
Net Cash From Continuing Investing Activities
-8.79 -161 40
Purchase of Property, Plant & Equipment
-0.62 -2.21 -1.13
Purchase of Investments
-55 -490 -365
Sale of Property, Plant & Equipment
- 0.00 0.07
Sale and/or Maturity of Investments
47 331 406
Net Cash From Financing Activities
58 337 141
Net Cash From Continuing Financing Activities
58 337 141
Repurchase of Common Equity
-1.65 -3.36 -0.48
Issuance of Debt
- 0.00 25
Issuance of Common Equity
0.00 341 116
Other Financing Activities, net
-0.14 -0.70 1.04
Cash Interest Paid
0.19 0.14 0.42

Quarterly Cash Flow Statements for Kyverna Therapeutics

This table details how cash moves in and out of Kyverna Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents
190 -93 -27 -8.05 -40 -3.43 -19 90 -92 -0.39 0.01
Net Cash From Operating Activities
-26 -24 -27 -37 -45 -32 -43 -34 -42 -40 -35
Net Cash From Continuing Operating Activities
-26 -24 -27 -37 -45 -32 -43 -34 -42 -40 -35
Net Income / (Loss) Continuing Operations
-27 -29 -34 -37 -45 -42 -37 -38 -40 -38 -42
Consolidated Net Income / (Loss)
-27 -29 -34 -37 -45 -42 -37 -38 -40 -38 -42
Depreciation Expense
0.48 0.53 0.56 0.56 0.50 0.52 0.42 0.37 0.35 0.43 0.27
Amortization Expense
-0.28 -2.26 -2.89 -2.24 -2.11 -1.84 -1.57 -1.37 -0.73 -0.19 -0.19
Non-Cash Adjustments To Reconcile Net Income
2.28 2.47 4.09 2.07 3.51 3.23 0.98 3.54 3.90 3.92 4.56
Changes in Operating Assets and Liabilities, net
-1.32 3.89 5.25 0.03 -2.18 8.23 -6.36 1.74 -5.39 -6.15 1.93
Net Cash From Investing Activities
-123 -68 0.68 29 5.58 29 23 -17 -50 36 29
Net Cash From Continuing Investing Activities
-123 -68 0.68 29 5.58 29 23 -17 -50 36 29
Purchase of Property, Plant & Equipment
-0.54 -1.03 -0.10 -0.53 0.00 -0.20 -0.39 -0.54 0.00 -0.55 -0.53
Purchase of Investments
-145 -80 -138 -127 -81 -95 -73 -116 -116 -32 -46
Sale and/or Maturity of Investments
23 13 138 157 87 124 96 99 66 69 75
Net Cash From Financing Activities
338 -0.57 -0.15 -0.22 -0.41 -0.65 1.49 141 -0.10 3.79 6.86
Net Cash From Continuing Financing Activities
338 -0.57 -0.15 -0.22 -0.41 -0.65 1.49 141 -0.10 3.79 6.86
Repurchase of Common Equity
-2.96 -0.41 - - -0.08 -0.34 - -0.06 -0.07 -0.07 -0.16
Issuance of Common Equity
341 - - - 0.00 - - 116 0.00 2.49 6.50
Other Financing Activities, net
-0.17 -0.16 -0.15 -0.22 -0.34 -0.31 1.49 0.20 -0.03 1.37 0.51
Cash Interest Paid
0.04 0.04 0.03 0.03 0.02 0.02 0.01 0.37 0.57 0.57 0.58

Annual Balance Sheets for Kyverna Therapeutics

This table presents Kyverna Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
Total Assets
75 305 294
Total Current Assets
61 291 283
Cash & Equivalents
35 97 124
Short-Term Investments
23 189 155
Prepaid Expenses
3.12 4.62 3.70
Plant, Property, & Equipment, net
2.33 3.35 1.55
Total Noncurrent Assets
12 11 9.33
Noncurrent Note & Lease Receivables
1.79 0.84 0.31
Other Noncurrent Operating Assets
10 9.86 9.02
Total Liabilities & Shareholders' Equity
75 305 294
Total Liabilities
26 38 62
Total Current Liabilities
20 34 36
Accounts Payable
4.36 4.62 5.31
Accrued Expenses
9.77 20 17
Current Employee Benefit Liabilities
2.81 4.88 9.99
Other Current Liabilities
2.92 3.94 3.97
Total Noncurrent Liabilities
6.16 4.30 25
Long-Term Debt
- 0.00 25
Other Noncurrent Operating Liabilities
6.16 4.30 0.32
Commitments & Contingencies
0.00 0.00 0.00
Total Equity & Noncontrolling Interests
-131 267 232
Total Preferred & Common Equity
-131 267 232
Preferred Stock
0.00 0.00 0.00
Total Common Equity
-131 267 232
Common Stock
4.64 530 657
Retained Earnings
-136 -264 -425
Accumulated Other Comprehensive Income / (Loss)
0.00 0.11 0.10

Quarterly Balance Sheets for Kyverna Therapeutics

This table presents Kyverna Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets
390 363 339 261 227 187 257 220 189
Total Current Assets
375 349 325 248 214 175 242 207 176
Cash & Equivalents
224 132 105 57 53 34 32 32 32
Short-Term Investments
146 215 217 186 158 137 204 168 139
Prepaid Expenses
5.69 2.59 3.79 5.00 2.65 3.79 5.28 7.12 5.69
Plant, Property, & Equipment, net
2.71 3.37 3.15 2.44 2.16 1.79 1.34 1.33 1.36
Total Noncurrent Assets
12 11 11 11 10 10 14 12 12
Noncurrent Note & Lease Receivables
1.55 1.32 1.08 0.60 0.37 0.21 0.20 0.11 0.05
Other Noncurrent Operating Assets
10 9.61 9.59 9.97 9.65 10 14 12 12
Total Liabilities & Shareholders' Equity
390 363 339 261 227 187 257 220 189
Total Liabilities
29 30 36 37 42 35 61 54 56
Total Current Liabilities
22 23 31 33 40 34 30 23 25
Accounts Payable
7.45 4.86 9.93 8.47 9.92 3.02 12 2.93 3.40
Accrued Expenses
9.33 12 13 18 21 20 13 13 13
Current Employee Benefit Liabilities
1.36 2.72 4.44 3.08 4.97 6.96 3.11 5.48 7.41
Other Current Liabilities
3.72 3.87 3.93 3.59 3.58 3.69 1.99 1.53 1.31
Total Noncurrent Liabilities
7.13 6.13 5.50 3.35 2.34 1.34 32 31 31
Long-Term Debt
- - - - - - 25 25 25
Other Noncurrent Operating Liabilities
7.13 6.13 5.50 3.35 2.34 1.34 6.96 6.59 6.19
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
361 334 303 224 184 152 196 166 133
Total Preferred & Common Equity
361 334 303 224 184 152 196 166 133
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
361 334 303 224 184 152 196 166 133
Common Stock
524 525 529 532 535 539 660 669 678
Retained Earnings
-163 -192 -226 -308 -350 -387 -465 -503 -545
Accumulated Other Comprehensive Income / (Loss)
-0.00 -0.04 0.15 -0.00 -0.02 0.03 -0.10 -0.14 -0.15

Annual Metrics And Ratios for Kyverna Therapeutics

This table displays calculated financial ratios and metrics derived from Kyverna Therapeutics' official financial filings.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding
0.00 43,171,612.00 43,796,170.00
DEI Adjusted Shares Outstanding
0.00 43,171,612.00 43,796,170.00
DEI Earnings Per Adjusted Shares Outstanding
0.00 -2.95 -3.68
Growth Metrics
- - -
Revenue Growth
0.00% 0.00% 0.00%
EBITDA Growth
0.00% -139.58% -18.06%
EBIT Growth
0.00% -128.45% -19.07%
NOPAT Growth
0.00% -128.51% -19.09%
Net Income Growth
0.00% -111.17% -26.54%
EPS Growth
0.00% 96.28% -9.31%
Operating Cash Flow Growth
0.00% -117.99% -34.54%
Free Cash Flow Firm Growth
0.00% 0.00% -30.68%
Invested Capital Growth
0.00% -131.80% -14.66%
Revenue Q/Q Growth
0.00% 0.00% 0.00%
EBITDA Q/Q Growth
0.00% -16.65% 1.38%
EBIT Q/Q Growth
0.00% -15.95% 1.03%
NOPAT Q/Q Growth
0.00% -15.99% 1.03%
Net Income Q/Q Growth
0.00% -15.20% -0.20%
EPS Q/Q Growth
0.00% 90.74% -1.39%
Operating Cash Flow Q/Q Growth
0.00% -19.32% 2.25%
Free Cash Flow Firm Q/Q Growth
0.00% 0.00% 3.14%
Invested Capital Q/Q Growth
0.00% -2.73% -15.85%
Profitability Metrics
- - -
Gross Margin
0.00% 0.00% 0.00%
EBITDA Margin
0.00% 0.00% 0.00%
Operating Margin
0.00% 0.00% 0.00%
EBIT Margin
0.00% 0.00% 0.00%
Profit (Net Income) Margin
0.00% 0.00% 0.00%
Tax Burden Percent
100.00% 100.00% 100.00%
Interest Burden Percent
96.65% 89.34% 94.94%
Effective Tax Rate
0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00%
Return on Equity (ROE)
-122.75% -80.74% -64.67%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
0.00% 0.00% 0.00%
Return on Assets (ROA)
0.00% 0.00% 0.00%
Return on Common Equity (ROCE)
327.98% -34.57% -64.67%
Return on Equity Simple (ROE_SIMPLE)
45.94% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-44 -100 -119
NOPAT Margin
0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)
-28.99% -16.10% -15.70%
Return On Investment Capital (ROIC_SIMPLE)
33.25% -37.44% -46.25%
Cost of Revenue to Revenue
0.00% 0.00% 0.00%
SG&A Expenses to Revenue
0.00% 0.00% 0.00%
R&D to Revenue
0.00% 0.00% 0.00%
Operating Expenses to Revenue
0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)
-62 -143 -170
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-62 -148 -175
Valuation Ratios
- - -
Price to Book Value (P/BV)
0.00 0.61 1.77
Price to Tangible Book Value (P/TBV)
0.00 0.61 1.77
Price to Revenue (P/Rev)
0.00 0.00 0.00
Price to Earnings (P/E)
0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00
Leverage & Solvency
- - -
Debt to Equity
0.00 0.00 0.11
Long-Term Debt to Equity
0.00 0.00 0.11
Financial Leverage
-1.17 -1.09 -1.08
Leverage Ratio
1.53 1.20 1.20
Compound Leverage Factor
1.48 1.07 1.14
Debt to Total Capital
0.00% 0.00% 9.63%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 9.63%
Preferred Equity to Total Capital
0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
367.19% 0.00% 0.00%
Common Equity to Total Capital
-267.19% 100.00% 90.37%
Debt to EBITDA
0.00 0.00 -0.14
Net Debt to EBITDA
0.00 0.00 1.45
Long-Term Debt to EBITDA
0.00 0.00 -0.14
Debt to NOPAT
0.00 0.00 -0.21
Net Debt to NOPAT
0.00 0.00 2.14
Long-Term Debt to NOPAT
0.00 0.00 -0.21
Altman Z-Score
2.73 0.80 1.09
Noncontrolling Interest Sharing Ratio
367.19% 57.19% 0.00%
Liquidity Ratios
- - -
Current Ratio
3.05 8.61 7.75
Quick Ratio
2.90 8.47 7.65
Cash Flow Metrics
- - -
Free Cash Flow to Firm (FCFF)
0.00 -89 -116
Operating Cash Flow to CapEx
-8,439.61% -5,181.41% -14,460.21%
Free Cash Flow to Firm to Interest Expense
0.00 -625.33 -237.29
Operating Cash Flow to Interest Expense
-280.27 -804.58 -314.34
Operating Cash Flow Less CapEx to Interest Expense
-283.59 -820.11 -316.51
Efficiency Ratios
- - -
Asset Turnover
0.00 0.00 0.00
Accounts Receivable Turnover
0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00
Fixed Asset Turnover
0.00 0.00 0.00
Accounts Payable Turnover
0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00
Capital & Investment Metrics
- - -
Invested Capital
-8.37 -19 -22
Invested Capital Turnover
0.00 0.00 0.00
Increase / (Decrease) in Invested Capital
0.00 -11 -2.84
Enterprise Value (EV)
442 -125 157
Market Capitalization
319 161 412
Book Value per Share
($195.06) $6.18 $5.30
Tangible Book Value per Share
($195.06) $6.18 $5.30
Total Capital
49 267 257
Total Debt
0.00 0.00 25
Total Long-Term Debt
0.00 0.00 25
Net Debt
-58 -286 -255
Capital Expenditures (CapEx)
0.62 2.21 1.06
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-17 -29 -33
Debt-free Net Working Capital (DFNWC)
41 257 246
Net Working Capital (NWC)
41 257 246
Net Nonoperating Expense (NNE)
17 28 42
Net Nonoperating Obligations (NNO)
-58 -286 -255
Total Depreciation and Amortization (D&A)
0.59 -5.53 -5.09
Debt-free, Cash-free Net Working Capital to Revenue
0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue
0.00% 0.00% 0.00%
Net Working Capital to Revenue
0.00% 0.00% 0.00%
Earnings Adjustments
- - -
Adjusted Basic Earnings per Share
$0.00 ($3.33) ($3.64)
Adjusted Weighted Average Basic Shares Outstanding
0.00 38.33M 44.26M
Adjusted Diluted Earnings per Share
$0.00 ($3.33) ($3.64)
Adjusted Weighted Average Diluted Shares Outstanding
0.00 38.33M 44.26M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
0.00 43.21M 60.44M
Normalized Net Operating Profit after Tax (NOPAT)
-44 -100 -119
Normalized NOPAT Margin
0.00% 0.00% 0.00%
Pre Tax Income Margin
0.00% 0.00% 0.00%
Debt Service Ratios
- - -
EBIT to Interest Expense
-334.02 -1,004.89 -347.47
NOPAT to Interest Expense
-233.61 -702.98 -243.11
EBIT Less CapEx to Interest Expense
-337.34 -1,020.42 -349.64
NOPAT Less CapEx to Interest Expense
-236.93 -718.51 -245.28
Payout Ratios
- - -
Dividend Payout Ratio
0.00% 0.00% 0.00%
Augmented Payout Ratio
-2.73% -2.64% -0.29%

Quarterly Metrics And Ratios for Kyverna Therapeutics

This table displays calculated financial ratios and metrics derived from Kyverna Therapeutics' official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding
0.00 43,115,244.00 43,146,852.00 43,171,612.00 43,214,918.00 43,218,873.00 43,245,667.00 43,796,170.00 60,439,893.00 60,795,212.00 61,843,444.00
DEI Adjusted Shares Outstanding
0.00 43,115,244.00 43,146,852.00 43,171,612.00 43,214,918.00 43,218,873.00 43,245,667.00 43,796,170.00 60,439,893.00 60,795,212.00 61,843,444.00
DEI Earnings Per Adjusted Shares Outstanding
0.00 -0.67 -0.80 -0.87 -1.03 -0.97 -0.85 -0.86 -0.66 -0.63 -0.68
Growth Metrics
- - - - - - - - - - -
Revenue Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth
-162.15% -172.99% -152.50% -98.17% -68.06% -30.06% 2.96% 5.72% 14.84% 14.05% -7.21%
EBIT Growth
-156.67% -151.39% -138.20% -91.68% -61.43% -32.80% 0.09% 4.32% 12.75% 10.93% -10.61%
NOPAT Growth
-156.51% -151.35% -138.12% -91.99% -61.48% -32.82% 0.11% 4.29% 12.74% 10.93% -10.77%
Net Income Growth
-139.55% -120.02% -123.03% -81.40% -67.22% -46.10% -6.65% -0.84% 10.99% 8.94% -14.01%
EPS Growth
90.74% 96.79% 96.56% 97.78% 8.04% -44.78% -6.25% -6.76% 35.92% 35.05% 20.00%
Operating Cash Flow Growth
-122.77% -114.76% -146.94% -99.65% -75.96% -32.16% -57.59% 9.54% 7.39% -26.16% 18.36%
Free Cash Flow Firm Growth
0.00% 0.00% 0.00% 0.00% -98.76% -54.69% -224.30% -39.27% -35.09% -178.50% -37.20%
Invested Capital Growth
0.00% 0.00% 0.00% -131.80% -111.73% -114.49% -1.67% -14.66% 13.87% 67.05% 35.08%
Revenue Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth
-35.40% -20.56% -16.96% -3.79% -14.83% 6.70% 12.73% -0.84% -3.73% 5.83% -8.85%
EBIT Q/Q Growth
-37.25% -13.86% -16.01% -5.72% -15.59% 6.33% 12.72% -1.25% -5.40% 4.38% -8.39%
NOPAT Q/Q Growth
-37.33% -13.89% -15.96% -5.86% -15.51% 6.32% 12.80% -1.43% -5.31% 4.38% -8.45%
Net Income Q/Q Growth
-29.16% -7.90% -19.75% -8.69% -19.06% 5.72% 12.58% -2.76% -5.09% 3.55% -9.45%
EPS Q/Q Growth
96.64% 40.18% -19.40% 7.50% -39.19% 5.83% 12.37% 7.06% 16.46% 4.55% -7.94%
Operating Cash Flow Q/Q Growth
-37.50% 5.29% -13.71% -34.82% -21.19% 28.87% -35.59% 22.61% -24.07% 3.10% 12.25%
Free Cash Flow Firm Q/Q Growth
0.00% 9.12% 22.62% -114.27% -31.90% 29.27% -62.24% 7.98% -27.93% -45.82% 20.07%
Invested Capital Q/Q Growth
-5.22% -44.59% -48.31% -2.73% 3.88% -46.47% 29.70% -15.85% 27.80% 43.97% -38.52%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent
90.84% 86.09% 88.86% 91.35% 94.10% 94.71% 94.86% 96.28% 95.99% 96.83% 97.78%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
-21.03% -27.47% -36.55% -80.74% -49.72% -61.29% -70.82% -64.67% -74.55% -87.24% -110.69%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)
-21.03% -27.47% -36.55% -34.57% -49.72% -61.29% -70.82% -64.67% -74.55% -87.24% -110.69%
Return on Equity Simple (ROE_SIMPLE)
-21.03% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-21 -23 -27 -29 -33 -31 -27 -27 -29 -28 -30
NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)
-3.32% -3.12% -4.57% -5.10% -3.74% -3.94% -3.93% -3.81% -4.74% -5.50% -7.52%
Return On Investment Capital (ROIC_SIMPLE)
-5.69% -7.02% -8.97% -10.78% -14.81% -16.86% -17.84% -10.70% -13.14% -14.54% -18.99%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)
-29 -33 -39 -41 -47 -44 -39 -39 -41 -40 -43
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-29 -35 -41 -43 -49 -46 -40 -40 -42 -39 -43
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
1.00 0.97 0.70 0.61 0.37 0.72 1.71 1.77 2.67 3.27 3.16
Price to Tangible Book Value (P/TBV)
1.00 0.97 0.70 0.61 0.37 0.72 1.71 1.77 2.67 3.27 3.16
Price to Revenue (P/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.11 0.13 0.15 0.19
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.11 0.13 0.15 0.19
Financial Leverage
-1.02 -1.04 -1.06 -1.09 -1.05 -1.08 -1.08 -1.08 -1.08 -1.10 -1.11
Leverage Ratio
1.08 1.09 1.12 1.20 1.11 1.14 1.16 1.20 1.23 1.28 1.32
Compound Leverage Factor
0.98 0.94 1.00 1.10 1.05 1.08 1.10 1.16 1.18 1.24 1.29
Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 9.63% 11.26% 13.07% 15.79%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 9.63% 11.26% 13.07% 15.79%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 90.37% 88.74% 86.93% 84.22%
Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.14 -0.15 -0.15 -0.15
Net Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.45 1.26 1.08 0.89
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.14 -0.15 -0.15 -0.15
Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.21 -0.22 -0.22 -0.22
Net Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 2.14 1.85 1.57 1.28
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.21 -0.22 -0.22 -0.22
Altman Z-Score
7.71 6.59 3.20 1.90 0.10 0.00 1.75 2.55 3.02 3.19 0.67
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 57.19% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
17.17 14.86 10.50 8.61 7.44 5.39 5.16 7.75 8.15 9.06 7.01
Quick Ratio
16.91 14.75 10.38 8.47 7.29 5.32 5.05 7.65 7.97 8.75 6.79
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-12 -11 -8.26 -18 -23 -17 -27 -25 -32 -46 -37
Operating Cash Flow to CapEx
-4,700.74% -2,351.65% -26,950.00% -6,966.35% 0.00% -15,661.27% -11,051.28% -6,243.39% 0.00% -7,355.11% -6,736.57%
Free Cash Flow to Firm to Interest Expense
-266.99 -273.76 -258.19 -655.66 -933.98 -1,179.64 -3,827.70 -55.66 -47.29 -68.24 -50.50
Operating Cash Flow to Interest Expense
-580.11 -619.87 -859.03 -1,372.63 -1,796.60 -2,282.07 -6,188.71 -75.68 -62.36 -59.80 -48.58
Operating Cash Flow Less CapEx to Interest Expense
-592.45 -646.23 -862.22 -1,392.33 -1,796.60 -2,296.64 -6,244.71 -76.89 -62.36 -60.61 -49.30
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
-8.80 -13 -19 -19 -19 -27 -19 -22 -16 -9.00 -12
Invested Capital Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital
-8.80 -13 -19 -11 -9.84 -15 -0.32 -2.84 2.59 18 6.73
Enterprise Value (EV)
-9.61 -23 -111 -125 -159 -79 88 157 310 367 275
Market Capitalization
360 323 211 161 83 133 259 412 522 542 421
Book Value per Share
$15.20 $7.74 $7.02 $6.18 $5.18 $4.27 $3.51 $5.30 $3.24 $2.72 $2.15
Tangible Book Value per Share
$15.20 $7.74 $7.02 $6.18 $5.18 $4.27 $3.51 $5.30 $3.24 $2.72 $2.15
Total Capital
361 334 303 267 224 184 152 257 220 190 158
Total Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 25 25 25 25
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 25 25 25 25
Net Debt
-370 -346 -322 -286 -243 -212 -171 -255 -212 -175 -146
Capital Expenditures (CapEx)
0.54 1.03 0.10 0.53 0.00 0.20 0.39 0.54 0.00 0.55 0.53
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-16 -21 -27 -29 -28 -37 -30 -33 -24 -16 -19
Debt-free Net Working Capital (DFNWC)
354 325 294 257 214 175 141 246 212 184 151
Net Working Capital (NWC)
354 325 294 257 214 175 141 246 212 184 151
Net Nonoperating Expense (NNE)
6.14 5.40 7.35 8.76 11 11 9.68 10 11 11 12
Net Nonoperating Obligations (NNO)
-370 -346 -322 -286 -243 -212 -171 -255 -212 -175 -146
Total Depreciation and Amortization (D&A)
0.20 -1.73 -2.34 -1.67 -1.61 -1.33 -1.15 -1.00 -0.38 0.24 0.08
Debt-free, Cash-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($1.12) ($0.67) ($0.80) ($0.74) ($1.03) ($0.97) ($0.85) ($0.79) ($0.66) ($0.63) ($0.68)
Adjusted Weighted Average Basic Shares Outstanding
23.75M 43.13M 43.16M 38.33M 43.22M 43.23M 43.42M 44.26M 60.43M 60.90M 61.96M
Adjusted Diluted Earnings per Share
($1.12) ($0.67) ($0.80) ($0.74) ($1.03) ($0.97) ($0.85) ($0.79) ($0.66) ($0.63) ($0.68)
Adjusted Weighted Average Diluted Shares Outstanding
23.75M 43.13M 43.16M 38.33M 43.22M 43.23M 43.42M 44.26M 60.43M 60.90M 61.96M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
43.12M 43.15M 43.17M 43.21M 43.22M 43.25M 43.80M 60.44M 60.80M 61.84M 63.22M
Normalized Net Operating Profit after Tax (NOPAT)
-21 -23 -27 -29 -33 -31 -27 -27 -29 -28 -30
Normalized NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
-667.82 -857.90 -1,212.97 -1,519.89 -1,897.40 -3,173.64 -5,540.00 -88.64 -62.05 -58.72 -58.92
NOPAT to Interest Expense
-467.06 -600.12 -848.09 -1,064.03 -1,327.42 -2,220.50 -3,872.70 -62.07 -43.41 -41.08 -41.25
EBIT Less CapEx to Interest Expense
-680.16 -884.26 -1,216.16 -1,539.59 -1,897.40 -3,188.21 -5,596.00 -89.85 -62.05 -59.53 -59.64
NOPAT Less CapEx to Interest Expense
-479.40 -626.47 -851.28 -1,083.73 -1,327.42 -2,235.07 -3,928.70 -63.28 -43.41 -41.90 -41.97
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
-6.06% -5.46% -4.38% -2.64% -0.33% -0.26% -0.26% -0.29% -0.30% -0.13% -0.23%

Financials Breakdown Chart

Key Financial Trends

Kyverna Therapeutics remains a development-stage biotechnology company with no reported revenue. Revenue and gross profit were zero in every period provided, while operating expenses remained elevated. The company reported a $38.3 million net loss in Q2 2026, an improvement from losses of $39.7 million in Q1 2026 and $42.1 million in Q2 2025.

Operating expenses declined to $39.6 million in Q2 2026 from $41.4 million in Q1 and $44.4 million a year earlier. Research and development spending fell to $24.8 million from $30.1 million in Q2 2025, while selling, general and administrative expenses increased to $14.8 million from $8.6 million. Despite the lower total spending, Kyverna has not yet generated operating revenue or reached profitability.

Cash use remains the central financial risk. Operating cash flow was negative $40.3 million in Q2 2026, only modestly better than negative $41.6 million in Q1 but worse than negative $31.9 million in Q2 2025. The company ended the quarter with $31.8 million in cash and $167.6 million in short-term investments, or approximately $199.7 million in combined liquid resources. At the Q2 operating cash-burn rate, that represents roughly five quarters of liquidity before considering changes in spending, investment income, financing or clinical costs.

The balance sheet remains relatively lightly leveraged compared with the company’s asset base. Total liabilities were $54.3 million, including $24.9 million of long-term debt, against $219.8 million of total assets. However, total assets declined from $257.0 million at the end of Q1 2026 and $226.5 million at the end of Q2 2025, while the accumulated retained deficit expanded to $502.9 million.

  • Liquid resources remain substantial: Cash and short-term investments totaled approximately $199.7 million at June 30, 2026, providing a meaningful funding base for ongoing research and development.
  • Quarterly losses improved: The Q2 2026 net loss of $38.3 million was smaller than the $39.7 million loss in Q1 and the $42.1 million loss in Q2 2025.
  • Operating expenses moderated: Total operating expenses declined to $39.6 million in Q2 2026 from $44.4 million a year earlier, primarily because of lower research and development spending.
  • Liquidity exceeds near-term liabilities: Total current assets of $206.5 million were approximately nine times total current liabilities of $22.8 million, indicating strong short-term balance-sheet coverage.
  • Investment income provides some offset: Interest and investment income was $1.9 million in Q2 2026, but this remains small relative to the company’s operating cash burn and depends on maintaining investable balances.
  • Investment portfolio activity affects reported cash: Kyverna generated $36.1 million of investing cash flow in Q2 through investment maturities and sales, partly offsetting operating cash use; this is not a recurring source of operating funding.
  • No commercial revenue has emerged: Kyverna reported zero revenue in all periods provided, leaving the company dependent on financing and existing capital to fund its operations.
  • Cash burn remains high and persistent: Operating cash flow has been negative in every quarter provided, with Q2 2026 use of $40.3 million following $41.6 million in Q1 and $43.3 million in Q3 2025.
  • The accumulated deficit continues to grow: Retained earnings declined to negative $502.9 million in Q2 2026 from negative $464.6 million at the end of Q1, reflecting continued losses.
  • Share count has increased materially: Weighted-average basic shares rose to 60.9 million in Q2 2026 from 43.2 million in Q2 2025 and 23.8 million in Q1 2024, indicating significant dilution for existing shareholders.

Overall, Kyverna’s balance sheet provides some near-term financial flexibility, and recent expense reductions are encouraging. However, the investment case remains dependent on clinical and commercial progress because the company continues to report no revenue, substantial recurring losses and significant operating cash outflows. Continued financing or asset sales may eventually be necessary if the current burn rate persists.

11/17/26 03:35 PM ETAI Generated. May Contain Errors.

Kyverna Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Kyverna Therapeutics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Kyverna Therapeutics' net income appears to be on a downward trend, with a most recent value of -$161.31 million in 2025, falling from -$60.37 million in 2023. The previous period was -$127.48 million in 2024. See where experts think Kyverna Therapeutics is headed by visiting Kyverna Therapeutics' forecast page.

Kyverna Therapeutics' total operating income in 2025 was -$169.83 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $169.83 million

Over the last 2 years, Kyverna Therapeutics' total revenue changed from $0.00 in 2023 to $0.00 in 2025, a change of 0.0%.

In the past 10 quarters, Kyverna Therapeutics' cash and equivalents has ranged from $31.81 million in Q2 2026 to $224.29 million in Q1 2024, and is currently $31.82 million as of their latest financial filing in Q3 2026.

Kyverna Therapeutics had total debt of $24.74 million at the end of 2025, compared with none in 2024, and none in 2023.

Over the last 2 years, Kyverna Therapeutics' book value per share changed from -195.06 in 2023 to 5.30 in 2025.



Financial statements for NASDAQ:KYTX last updated on 11/12/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners